Onc 3 Sales Force

1) Lost Zoladex
2) Lost Ethyol
3) Lost Faslodex to Onc 1
4) Losing Casodex (patent expires Oct 1, 2008 without pediatric extension)
5) Two oncology RSDs are being rolled into one on the East Coast.
6) Zactima has been delayed.
7) Arimidex goes generic June 2010.
8) Managers say we are 'right sized'.
9) That's what they told the hospital force.

Here is the FDA link for Casodex patent expiration:

http://www.accessdata.fda.gov/script...1&table1=OB_Rx

sh*t!!!!

Have no fear, a displaced Hospital DM is coming to the rescue in Orlando.

When will we know if the patent expiration is granted or denied? Six more months is job security for a while.

1.) Faslodex patent expires in 2021
2.) Zactima launch should be known by December 2008- Thyroid-2009,
3.) Recentin scheduled fourth quarter of 2009/10 - Glioblastoma
4.) ZD-4054 scheduled 2010- Prostate
5.) AZD 6244- scheduled 2011 malignant melanoma
6.) several co-promote probabilites


Quit selling fear when actually there is alot to be thankful for, providing you are content with your position which it doesn't sound like the OP is.

April 1st , 2009 Casodex is done. What's next ?

Originally Posted by Anonymous

Have no fear, a displaced Hospital DM is coming to the rescue in Orlando.

I worked with Mary Van Horn (ex Hendrickson) as a PSS and I can assure you she will not be saving anything. She was weak as a PSS but excellent in taking credit for others work and successes. This person should not be handed a specialty job just because she failed as a DM. I pity whoever it is she will be working with because they will feel like a babysitter every time they have to take her by the hand and explain to her "again" what she's supposed to be doing. Bad choice by AZ to put this one in Oncology. Did the DM even have a choice here or was this assigned to the poor fool. Look out below AZ, off-label Mary is back in the field.

What happened to the Onc 3 rep in Orlando? Was this person displaced or managed out? Something is very strange in Florida.

http://uk.reuters.com/article/rbssHe...081119?sp=true

"AstraZeneca said its trial for Zactima, one of a new class of drugs called TK inhibitors, met its key goal in combination with Sanofi-Aventis's (SASY.PA: Quote, Profile, Research) chemotherapy treatment Taxotere, but not with Eli-Lilly's (LLY.N: Quote, Profile, Research) Alimta.

The results also showed the drug did not perform better than Roche Holding (ROG.VX: Quote, Profile, Research) Genentech Inc's (DNA.N: Quote, Profile, Research) and OSI Pharmaceuticals' (OSIP.O: Quote, Profile, Research) Tarceva, the first of the TK inhibitors.

Analyst Simon Mather said that the results meant the drug would be useful in about 40 percent of second line patients suffering from non small cell lung cancer, the most common form of lung cancer.

"Initial headlines indicate that the product may be useful in approximately 40 percent of the estimated 50,000 second line NSCLC patients, i.e those who currently receive Taxotere or pemetrexed (Alimta) as a monotherapy," he said, adding that the results were broadly in line with his expectations.

However, Deutsche Bank analysts said in a note that "with Alimta and Tarceva moving into a 1st-line maintenance setting and other new agents on the way, we view Zactima as having largely missed its commercial opportunity in lung."

Overall, the tests, whose primary goal was prolonged progression free survival in non small cell lung cancer, showed that there were advantages to combining the drug with chemotherapy treatments, the company said.

AstraZeneca suffered a disappointment in February this year when its lung cancer drug Recentin failed to meet goals in mid-stage trials"

Score another ) for R&D and the SSLT!! Not a bad batting average .1000!

ok..I am not a sky is falling type person, however, after reading the AZ intranet page this morning I do not have a very good feeling about the future size of oncology

whats the conf call on tuesday am all about?

Originally Posted by Anonymous

whats the conf call on tuesday am all about?

Realignment and displacements. Translated demotions to MC and layoffs for the rest. Now are you happy. You wanted bad news so here it is.

this sucks--is the conference call throughout the whole country?

Goodbye Onc 1, we hate to see you go. Remember it's all about delivering a solid core message with a consistent close. Good selling!! R&D apparently has no accountability for delivering products that can be marketed.

What do you think...will they get us down to one rep per territory? We don't need two...crap.

does onc 1 have the teleconference tomorrow?

Yes. I know but sworn to secrecy. Press release may go out tonight. Get a good night's sleep.

Originally Posted by Anonymous

What do you think...will they get us down to one rep per territory? We don't need two...crap.

MCL isn't such a bad place. I would prefer Hospital or CNS but Hospital just down sized and displaced took the best vacant spots. We are screwed. It had to happen because they cannot justify us any longer. It was a good ride while it lasted.

Originally Posted by Anonymous

Yes. I know but sworn to secrecy. Press release may go out tonight. Get a good night's sleep.

http://biz.yahoo.com/e/081124/abii8-k.html